41. Giant cell arteritis Clinical trials / Disease details
Clinical trials : 128 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04239196 (ClinicalTrials.gov) | July 1, 2020 | 19/11/2019 | Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA | Open Label Phase II Randomized Non-comparative Study of SC Tocilizumab Associated With IV Pulse Steroid Versus IV Pulse Steroid Alone for the Treatment of Acute Anterior Ischemic Optic Neuropathy Associated With Giant Cell Arteritis | Giant Cell Arteritis;Optic Ischaemic Neuropathy | Drug: tocilizumab and IV steroids combination;Other: IV steroids combination alone | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | Roche Chugai | Not yet recruiting | 50 Years | N/A | All | 58 | Phase 2 | France |